Communiqués AbbVie Inc.

Actions

ABBV

US00287Y1091

Produits pharmaceutiques

Marché Fermé - NYSE 22:04:14 01/10/2026			Varia. 5j.	Varia. 1 janv.
259,93 ^USD	-0,63%		-1,96%	+13,76%

01/10	AbbVie présente des données à long terme sur RINVOQ (upadacitinib) montrant une repigmentation continue dans le vitiligo non segmentaire	CI
30/09	AbbVie présente à l’EASD 2026 des données détaillées de phase 1 sur ABBV-295, un analogue de l’amyline à longue durée d’action, démontrant une bonne tolérance et un profil pharmacocinétique favorable	CI

Communiqués

01/10	AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo	PR
01/10	AbbVie to Host Third-Quarter 2026 Earnings Conference Call	PR
30/09	AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026	PR
30/09	AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026	PR
30/09	AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress	PR
29/09	AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development	PR
28/09	U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease	PR
24/09	EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma	AQ
22/09	AbbVie : Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued	PU
22/09	Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach	PR
22/09	AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis	PR
21/09	AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery	PR
18/09	AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026	PR
18/09	AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society Meeting	AQ
18/09	AbbVie - Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	AQ
17/09	AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting	PR
17/09	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	PR
15/09	AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum	AQ
15/09	AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign	PR
15/09	Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit	PR
10/09	AbbVie Declares Quarterly Dividend	PR
10/09	AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine	PR
03/09	AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma	PR
03/09	AbbVie Completes Acquisition of Apogee Therapeutics	PR
03/09	AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference	PR